Identification and validation of immunometabolic markers that increase the susceptibility to develop severe forms of SARS-COV-2 infection.

  • Funded by Consejo Nacional de Ciencia y Tecnología (CONACYT)
  • Total publications:5 publications

Grant number: 311880

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    -99
  • Known Financial Commitments (USD)

    $0
  • Funder

    Consejo Nacional de Ciencia y Tecnología (CONACYT)
  • Principal Investigator

    N/A

  • Research Location

    Mexico
  • Lead Research Institution

    N/A
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Development And Validation Of Diagnostic Or Prognostic Tools, Sensitive And Specific

Publicationslinked via Europe PMC

The plasma metabolome of long COVID patients two years after infection.

miR-146a, miR-221, and miR-155 are Involved in Inflammatory Immune Response in Severe COVID-19 Patients.

Immunometabolic signatures predict risk of progression to sepsis in COVID-19.

Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.

Clinical Factors Associated with COVID-19 Severity in Mexican Patients: Cross-Sectional Analysis from a Multicentric Hospital Study.